N.G.INDUSTRIES LTD. is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 18 | 19 | 17 | 17 | 16 |
| EBITDA (ex other income) | 2 | 2 | 2 | 2 | 2 |
| margin % | 12.4 | 9.7 | 11.6 | 10.9 | 10.9 |
| Owners' profit | 3 | 8 | 5 | 8 | 2 |
| EPS, as reported (₹) | 7.79 | 24.82 | 15.02 | 23.10 | 5.17 |
| ROE % · ROCE % | 10.9 · 13.1 | 29.5 · 33.5 | 13.9 · 15.4 | 20.1 · 23.4 | 5.2 · 6.3 |
| Debt / equity (x) | 0.02 | 0.02 | 0.03 | 0.05 | 0.05 |
| Cash from operations | (2) | 3 | (1) | 2 | 1 |
| Capex | (1) | (0) | (1) | (1) | (0) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | 3 | 8 | (3) | 0 | 1 | 1 | 1 | 1 |
| Net profit | 3 | 7 | (2) | 0 | 0 | 0 | 1 | 0 |
| EPS (₹) | 8.85 | 20.03 | 7.26 | 0.58 | 1.28 | 1.27 | 2.05 | 1.16 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 | 33.9 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Newspaper notice for FY25-26 Annual Report dispatch and 32nd AGM | compliance | minimal | — | — |
| 31 Aug 2026 · N G Industries 32nd AGM on Sep 26, 2026 with FY26 results | board shareholder meetings | low | — | — |
| 31 Aug 2026 · N.G. Industries Annual Report FY26: profit turnaround, dividend declared | results | high | — | — |
| 31 Aug 2026 · Record date fixed for FY 2025-26 dividend at N.G. Industries | corporate actions | medium | — | — |
| 28 Aug 2026 · Newspaper Publication of 32nd AGM Notice | compliance | minimal | — | — |
| 14 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| 6 Aug 2026 · Board meeting on Aug 13 2026 to approve Q1 FY27 results | results | low | — | — |
| 31 Jul 2026 · Newspaper Notice on SEBI Special Window for Physical Share Transfers | compliance | minimal | — | — |
| 11 Jul 2026 · Routine compliance certificate for Q1 FY27 filed with stock exchanges | compliance | minimal | — | — |
| 9 Jul 2026 · Newspaper notice for transfer of unclaimed FY 2018-19 dividend and shares to IEPF | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| NEPHROCARE HEALTH SERV L |
| 7,678 |
| 79.3 |
| 6.88 |
| 30.4 |
| 6.9 |
| 8.6 |
| — |
| 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 20.1 | 23.2 | 13 of 29 | 57% |
| P/B | 1.2 | 2.3 | 7 of 24 | 74% |
| ROCE | 6.1 | 6.1 | 15 of 29 | 50% |
| ROE | 5.2 | 7.3 | 15 of 26 | 44% |
| Debt / Equity | 0.1 | 0.0 | 15 of 26 | 44% |
| EBITDA margin | 15.2 | 25.6 | 16 of 24 | 35% |
| Revenue growth | 13.8 | 20.8 | 16 of 25 | 38% |
| Profit growth | 99.9 | 22.0 | 3 of 25 | 92% |
| Market cap | 39 | 38 | 15 of 30 | 52% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
